<SEC-DOCUMENT>0001188112-11-001793.txt : 20110623
<SEC-HEADER>0001188112-11-001793.hdr.sgml : 20110623
<ACCEPTANCE-DATETIME>20110623172337
ACCESSION NUMBER:		0001188112-11-001793
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110617
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110623
DATE AS OF CHANGE:		20110623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		11928491

	BUSINESS ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631 444 6861

	MAIL ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t70997_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>t70997_8k.htm</title>
    <!-- Licensed to: TrIState Financial -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>

<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">______________________</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">FORM 8-K</font><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of report (Date of earliest event reported): June 17, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Applied DNA Sciences, Inc</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact Name of Registrant as Specified in Charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of Incorporation)</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">002-90539</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">59-2262718</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">25 Health Sciences Drive, Suite 215</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stony Brook, New York 11790</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices) (Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">631-444- 8090</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Not Applicable</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former Name or Former Address, if Changed Since Last Report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.01&#160;&#160;Entry into a Material Definitive Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On June 17, 2011, Applied DNA Sciences, Inc. (the &#8220;Company&#8221;) received approval and permission to disclose from the Defense Logistics Agency of the U.S. Department of Defense (the &#8220;DLA&#8221;) a time and material subcontract (the &#8220;Subcontract&#8221;) that the Company entered into on June 2, 2011 with the Logistics Management Institute (&#8220;LMI&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of the Subcontract, the Company will perform work and services for LMI and the DLA relating to a program to demonstrate the functional, technical and business viability of DNA marking technology as an anti-counterfeiting measure by using it in the DLA microcircuit supply chain.&#160;&#160;The program is divided into six tasks and involves the preparation, implementation and evaluation of marking materials for microcircuit chips and packages, creation of a business case analysis, development of a pricing and transition plan and identification of feasible techniques to apply DNA marks in conjunction with laser marking.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The period of performance of the Subcontract is from May 26, 2011 through November 26, 2012.&#160;&#160;The Company is entitled to receive payments for performance under the Subcontract through November 26, 2012, for a total amount not to exceed $913,400.00, assuming the successful completion of the six tasks of the program.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of the press release issued by the Company on June 22, 2011 relating to the Subcontract is attached as Exhibit 99.1 and is incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 72pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit 99.1</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Press Release issued by Applied DNA Sciences, Inc. on June 22, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font id="TAB1" style="MARGIN-LEFT: 230.4pt"></font>Applied DNA Sciences, Inc.</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 230.4pt"></font>(Registrant)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 230.4pt"></font>By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ James A. Hayward&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</font></font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 230.4pt"></font>James A. Hayward</font></div>

<div style="TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 230.4pt"></font>Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date: June 23, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!-- Licensed to: TrIState Financial -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 99.1</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><img src="img00.jpg" alt=""></font></div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PRESS RELEASE </font></div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 22, 2011</font></div>
</div>
</td>
<td valign="top" width="85%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; BORDER-TOP: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For Immediate Release</font> </font></font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contact:</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investor&#160;Relations</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">631-444-8090</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">fax 631-444-8848</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Applied DNA Sciences</font></font></font></div>
</td>
<td width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="1%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="98%" style="BORDER-BOTTOM: black 0.5pt solid">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><br>
 </font>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Applied DNA Sciences Successfully Marks Mission-Critical Microchips <br>
for the Department of Defense</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stellar Results Lead to Immediate Marking Program with Defense Logistics Agency<br>
&#160;<br>
</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">STONY BROOK, N.Y., June 22, 2010/Marketwire/ - Applied DNA Sciences, Inc. (OTCBB: APDN) has successfully completed a program to DNA mark microchips for the Defense Logistics Agency of the U.S. Department of Defense.&#160;&#160;Used systematically, DNA marking could prevent counterfeit microchips, which might be defective and possibly dangerous, from entry at any point in the Department of Defense's supply chain.<br>
&#160;</font><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The initial results were so successful that APDN has already been awarded a follow-on contract of almost $1 million to fully engage one of the government's microchip supply chains.&#160;&#160;With interim deliverables that must be met, this final phase will include several Original Chip Manufacturers, distributors, board builders, system integrators and the Armed Forces.&#160;&#160;By including the various supply chain participants, APDN can partner with government and industry to build a forensically secure supply chain from the source to the end-user.&#160;&#160;APDN believes that the project could be a significant first step for the company toward a major role in supply chain defense with government, and in business-to-business relationships with Original Chip Manufacturers, distributors, and the manufacturers of printed circuit boards and finished electronic goods.<br>
&#160;</font><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results tell the story</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">APDN announced in a previous press release that it began marking microchips for a "government agency" which we did not name at the time. Our results in that first program demonstrated the ease of applying the forensic, botanical SigNature&#174; DNA taggants at an Original Chip Manufacturer.&#160;&#160;&#160;Once marked with DNA taggants, each microchip carries a "built-in" certificate of conformance to ensure authenticity and guard against counterfeiting.</font><br>
&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The initial marking program proceeded in this way:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An Original Chip Manufacturer marked 100% of its production for a period of two months. The microchips themselves were scanned at the Original Chip Manufacturer facility, the DNA-marked outer packaging was scanned at a Distributor.&#160;&#160;In a blind sampling, where both marked and unmarked chips were sampled, forensic analysis confirmed the authenticity of products DNA-marked as genuine.<br>
&#160;</font><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">Results:<br>
&#160;</font></font><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100% distinction was made between DNA-marked and unmarked product and packaging</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;100% forensic authentication of DNA-marked product and packaging</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No change was necessary to the production process</font></font></div>
</div>

<div>&#160;</div>
</td>
<td width="1%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-RIGHT: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%">&#160;</div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>

</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font></font>
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 99.1</font></font></div>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="1%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="98%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-TOP: black 0.5pt solid">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><br>
 </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No adverse impact to mark-permanency quality assurance test results at the Original Chip Manufacturer</font></font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Marks were rapidly scanned without difficulty at both the Original Chip Manufacturer and the distributor</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Marking was entirely non-destructive, as planned<br>
&#160;</font><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A Cost Effective Approach to Preventing After-Market Counterfeits from Entering the Supply Chain</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pricing efficiency is attained even with modest volume levels, allowing for an Original Chip Manufacturer to mark entire production runs with minimal costs, yet securing maximum protection.&#160;&#160;The benefit of DNA marking at the point of manufacture can then be shared by any and all participants in the supply chain through to the end-user, because non-destructive testing allows for absolute distinction between authentic and counterfeit product.&#160;&#160;Every participant in the supply chain can then share the benefits of DNA marking, from the Original Chip Manufacturer to the end-user.</font><br>
&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">APDN CEO James Hayward commented: "Securing the complete supply chain for a ubiquitous technology like microchips generates an immediate return on investment in business-to-business relationships with the Original Chip Manufacturers, the electronic distributors and the builders of circuit boards.&#160;&#160;When it comes to protecting our government and military supply chains, this is a return on investment measured not just in dollars, but in American lives saved."</font><br>
&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">War Fighter Support</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As stated in the Defense Logistics Agency's 2011 Director's Guidance Report <font style="TEXT-DECORATION: underline">(http://www.dla.mil/library/guidance_2011.pdf</font>), one of the Defense Logistics Agency's three strategic focus areas is 'War Fighter Support Enhancement' and an expected action is to "conduct an extensive Defense Logistics Agency operational evaluation team assessment and implement corrective actions as appropriate, including <font style="TEXT-DECORATION: underline">refined counterfeit-part risk-mitigation strategies</font>."&#160;</font><br>
&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As the former Director of the Defense Logistics Agency, retired Vice Admiral Ed Straw, commented, "Government and industry share a common interest in partnering to solve the issue of counterfeit microchips.&#160;&#160;DNA marking represents a proactive technical step forward as a detection and prevention strategy against the growing problem of counterfeits.&#160;&#160;Knowing how the War Fighters rely on microchips, I am proud to see this logistical security being led by the Defense Logistics Agency."<br>
&#160;</font><br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For photos and other media, please see our <font style="TEXT-DECORATION: underline">social media press release</font>.</font><br>
&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Defense Logistics Agency</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Defense Logistics Agency is the Department of Defense's largest logistics combat support agency, providing worldwide logistics support in both peacetime and wartime to the military services as well as several civilian agencies and foreign countries.&#160;&#160;The Agency sources and provides nearly 100 percent of the consumable items America's military forces need to operate . . . from food, fuel and energy, to uniforms, medical supplies, and construction and barrier equipment. Defense Logistics Agency also supplies about 84 percent of the military's spare parts.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</font></div>
</div>
</td>
<td width="1%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font>
<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="1%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-LEFT: black 0.5pt solid; BORDER-TOP: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="98%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-TOP: black 0.5pt solid">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><br>
 </font>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About APDN</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">APDN sells patented DNA security solutions to protect products, brands and intellectual property from </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied, and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to <font style="TEXT-DECORATION: underline">www.adnas.com</font> where APDN routinely posts all press releases.&#160;</font><br>
&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q.&#160;&#160;APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.</font><br>
&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">INVESTOR CONTACT: Debbie Bailey, 631-444-8090, <br>
fax: 631-444-8848 MEDIA COTACT: Janice Meraglia 631-444-6293, <br>
fax 631-444-8848 Web site: <font style="TEXT-DECORATION: underline">http://www.adnas.com</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FCMN Contact: <font style="TEXT-DECORATION: underline">info@adnas.com</font></font><br>
&#160;</font></div>
</div>
</td>
<td width="1%" style="BORDER-BOTTOM: black 0.5pt solid; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: black 0.5pt solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>
</div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img00.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``I`6(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_**_/C_@
MIC_P<>_!/_@G'\61\.!I_B/XG_$F(I]MT+PTL;#2MPW!)YG.U92N&\I`S@,I
M8*&!,O\`P3*_X..O@9_P4I^*:?#RUM?$GPX^(]PC266A>)8HT&K!4WNMM-&Q
M5W5,MY;['*@E58*Q`%S]`J*\>_;D_;N^&G_!.OX"WOQ%^*>O+HNA6THM;:*-
M1+>:K=,K,EK;19!DE94<XR`%5F8JJDC\U?!O_!YM\$=6\7Z>-?\`A1\6O#/@
M[5)S##XBF@MKA%PV"[1(^2JX;<(VD8;>%8\4P/V+HKF_AG\8O"WQD^%VE>-O
M"^OZ7KGA+6[)=1LM6M9U:UGMRN[S`_0`#.<X*D$'!!K\N_VC?^#OKX#_``O^
M+&J^%OA[X+\??&&+1-PNM9T2.*#3I-C%7:%I"9)(U.T>9L5&W95F7!*`_6BO
MAK]DO_@L-?\`[3?_``5N^,W[,4OP_M-'L_A/8W%XOB-=::>74C'-:QA#;&!1
M&"+DDGS6QY8&#NROH7_!,#_@KW\'_P#@K'\.=0UGX;ZA?VFM:"4&M>'-7B6#
M4]*WE@CLJLR21/M.V2-F7C!VME1^=_\`P2C_`.5K?]L;_L#7O_I7IM,&?IO\
M#_\`@IU\$/VC?VK/''P4\'>.K#6?B-\/-W]L:8D4BJIC8),(I64),89&$<@0
MDQN<'!S7OE?G#^P'\6?V=O$O_!;/]I'PIX$^"I\(_&+P_!)+XF\8M<K)%K(,
MT`E$$63Y)ED=))-H7S&3<V3S6_\`\%/O^#C#X(_\$S/BO%\.;VR\2?$7XE$1
M-=Z!X<CC9M+$J;H5N)78*LL@*%8D#R;75BH#(6`N??\`17YY?\$T/^#DCX*?
M\%&?C0/AD^D^*/AA\1KG?]@T?Q(D8352@+-%!,C8\X("WENJ,0#MW8->Z_\`
M!3/_`(*S?"#_`()1_##3_$/Q/U2^DU#7FDCT30-*@%QJFLM&%,AC1F5%1-R[
MI)&5`649+,JD"YZ%^W/^TG-^QW^QY\2?BI!HZ>()O`&@76MKIKW#6ZWODH7\
MLR*CE,X^]M..O2O/_P#@D?\`\%`;K_@IW^P[X<^,5WX5@\&2Z_>7UK_9<.HF
M_6(6US)!N\TQQY+;,XV\9ZFORN_;0_X.GOA!^V7^Q!\9_AEJWP^^(OPYU#QU
MX(U"W\,W^J6T5U::I/)$1%&?+RT>\E<.`R#)RZX!/US_`,&MGBO3O`O_``0C
M\$:UK%[!IVE:3>Z_=WEU.VV.WB34;EG=CV``)II-M12NV*4DE=GZ75\S_!G]
MON^^*W_!0/QW\%9/#5K96?@ZPENTU1;QI);IHWMUP8]@"@BX'<XV=\\>/^*O
M^#@CX:Z7XIN8-(\'^--?T&RE"3ZM%'%`NTG`=(W8'!["0QD^@KSC_@F]\6-$
M^.G_``63^*OB[PY<RW>B:]X=NKFTEDA:%V4S:>""K`$$$$'Z<9&#7VN$X5Q-
M#"XFOF%!Q2IMQ;Z2O'L]'9O1_<?+8GB"A5Q%"E@JJ=YI22ZJS[K:_5?>?I_1
M7RS^V#_P5G^'_P"R5\0_^$..GZWXP\71"-[K3])12+)67?B1V/W]F&V`$X9<
MX!S72?L/_P#!2+P!^W3;7MKX?-[I'B32X1<7FBZ@%%PL1(4RQLI*RQAB%+#!
M4LNY5W+GY^>0YA#"_7I49*GH[VZ/9][/H[6/9CF^#EB/JL:BY^WFMUVOY;GT
M%17@'[:G_!2+X=?L.Q6MIXDGO=4\1ZA";BUT73562Z:/=M$DA8A8D)R`6.6V
MMM#;2!YG^SC_`,%M?AG\;?B):^%->TO7?`&M:A,EO:'50CVLTCD;(S(O,;-D
M8+J%Y'S<U='A[,JV&^MTJ,G3WO;IW2W:\TK$U<ZP-.O]6J54I]OT;V3\F?9=
M%?/7_!2S_@IA\-_^"6'[/)^(?Q'FU&:WN[Q=-TK2]-B$M]J]TR,XBB5BJJ`B
M.S.[*J@=<E0?FC]@S_@X37]L?]J;PQ\+/$/[._Q=^%-]XV^U-H>J:];[;&[6
M"U>Z)9G2(AFC0D",2?>7G!S7C'IW/T<K%^)'Q&T/X/\`P^USQ7XGU2UT7P[X
M;L9M3U/4+EML-G;0H9))6/HJJ3QSQ7S3_P`%/O\`@LY\%?\`@DYX>TN3XD:C
MJFH^(]>1I=,\-Z'`ESJEU$I(,Q5W1(H=PV[Y'7<<A=Q5@/%_V+O^"ZGPP_X*
MP?L^_M!3'X4^)[?PG\-/"+ZAKVF>(?LTL7B&TGM;MY;554LI5HH"#NX(F'&.
MH%SZU_8@_;X^%G_!17X.R>._A+XE7Q)X?M[Z33;EVMI;6>TN(PK-'+%*JNA*
MNCC(Y5U(X->QU\)?\&^'Q<^!?Q9_8)U#7O@+\,;CX1>!8_$]_%<:;?70N;BX
MN4CA+W4LQ=RQ,9C4;G.U8@,X`KP;]I'_`(.]_@1\*OB[J_A/X?>#/'GQBCT(
MNMWK.A)%%ILFQBLCP.Y+RQ*<#S=@C;=E692&(!^LU%?+G_!,#_@KW\'_`/@K
M'\.=0UGX;ZA?VFM:"4&M>'-7B6#4]*WE@CLJLR21/M.V2-F7C!VME1X]_P`%
M/_\`@XQ^#?\`P31^,<'PTET?Q-\3/B28XYKW0_#BQ-_9*R*'C2XE=OEE>,AU
MB56;:59@H=24!^@E%?%7_!*/_@NQ\'_^"LUYK6A>%8=;\(^//#L'VN^\,Z\L
M:7;P;@C3P,C%98T=E5L892R;E&X9W/\`@J%_P6O^"7_!)W3-.@^(FHZGJGBS
M6X&NM-\,Z)`MQJ5S"&*^<^]ECAB+`J&D<;BK!0VUL,+GUS17Q+_P26_X+?>#
M/^"MDGCUO#G@CQAX(MO`-M97=U<^(#`L-U'<^?M:-HV(PHMV))P,,/>OG#]I
M#_@[Y^!7PL^+^J^%/A]X)\>?&"+0FE6]UG1!##IS^6^QG@9B7FB!S^]VJA!4
MJ7#`T!<_6FBOES_@F!_P5[^#_P#P5C^'.H:S\-]0O[36M!*#6O#FKQ+!J>E;
MRP1V569)(GVG;)&S+Q@[6RH^8_VHO^#G7PA\*?VE_%/PR^%OP6^*/QWO_`=Y
M]@\1ZCX9MBUI83(SK*B;(Y&<HT;KN8(C,CX8A<E`?I_17CG[`O[9VC?\%`OV
M5/#/Q7T'1->\-Z=XD-S&--UF)8KVTDM[F6VD1U4D??B;!SR,'BOSQ_X.8O\`
M@N#XM_823P[\#/@L\T?Q>\>V:WMWJ4%LT]QHMC+(\$"6JX(:[GE1PI^8QK'G
M;NDC8,#[(_X*'_\`!9W]G_\`X)D:>(?B3XSA?Q1-$)K7POI"B^UFX4AMKF%3
MB&-BC`23%$)!`)/%?DMX\_X.//VS/^"G_C/4O"?['/P6O]!TJ-C`VL1Z>NL:
ME;98%))KF8"PL]R\;9%?&XXD/!'D7[''_!#WPUXC^'^L^(?VH?`?[6?B[XF>
M+1-+)_PC>@N8]&ED8_OI;JX)>[N\_.Q9?*!;'[S!8\AXM_X)/?M!?L7?$`>)
M?V2]:_:7TQ7G$CVNI^%[K0KR-=Q"1RO;22071"D9#HBD'ID[!Z[R''J/-[-_
M>K_=>YYO]KX-OEY_S_.UCZP^!'_!LA^U/^U5\6?#OQ#_`&J?VB]3AN=)U2WU
M:/3;+5KK6M3MS&_F;8YF9+>S<-PI@$BKDD5^]JKM4#).!C)ZFOYSOAK_`,''
M'[=?_!/2PM(?VDO@EJ7B_P`-1%(#J^L:%/H%W(Q;@"]AC-J[8XQY6XG&37VQ
M\$/^#OW]FGXPBPL[G0?B+X<UZ[3!L;ZTM/+,N.(XYA/L?<<*N=I8L/E%>=3H
M5*E14HKWGI9Z:]M;';.M"$'4;T^_\C]6J*^3W_X*J[7('[/_`.T;(`<!H_"(
MD1O<,LQ##T()!IT'_!51))XTD^`7[1T".X5I'\&DJF3C)Q*2?P!->G_J]F'_
M`#[_`!C_`)G#_;.#_G_!_P"1]744RUG^U6T4NR2/S%#;'&UER,X([$4^O&9Z
M=PHHHI`?AM_P9\>$O"GQ(U_]HOX@^-+.QU']H<>+2NLW.H1[M2L+6XW2NR!A
M^[\V\6Y\PIR6A0-]U:B_X.T_^$$_9\_:*_9>^*7AU--TCXUV/BE;UI[*)$O;
MW3[66"1)9]I!<)/M5"_7?*`<!J^A/^"A'_!M1;?'W]JF_P#CE\`_C!XB_9Z^
M)&O,TFMMI44IL]2E;&^9#!-#)`\A`,H!=)"-VP,69OGCXB?\&='B?XK6VC^)
MO%/[3_B/QC\5%OEFU?6M?T^6_MKBUC5?*@C$D[7&]2#^\>8KMP!&O6F!:_X.
M0/$7A/X@_P#!9[]B_P"'?Q6NU'PE5TU+6+>ZN%AL9#<Z@(6,^[`$9^S1*Y8\
M1LX&W))_5O\`;9^#/P?\4?L4>-O#_P`4=&\*0_"S3M"GEOH[ZWBBLM,ABC++
M-'P!$\9"LC)AE95*G.*_'7_@Y6_9RT;]K?\`X+H_LH?"_P`0W>IV&A^.](M-
M%O;G3FCCNX8IM3N$9XRZ,@8`\;E8>W:O0;K_`(-.?BM\0A;>"_'O[:7Q$\3?
M!JPN$>'P\UO=R.\*8\N,1S7DEO$R8`5O+=5P2$&2*&!\W_\`!,CXT_$'P;_P
M:=?M7S12WW]EZ5J]QHV@RNQ00VMZ-/BOXXB3]P"ZF;@??E?DG('Z=_\`!L;\
M-OAGX:_X)`?#34O`UCH1U/Q%;SS^*[NW16N[O4Q/*DJ7+$;RR`!%5N!&%V_*
M03E_\%J?V:O!7[&W_!NO\5/AO\/M*M?#?A+PIH5G::?:@&3.[4[9G=W)RTLK
MN[-(3EI)"3G.#\"?\$Z?^#=#XB?%G]ASX6?%7X&_M3?$#X.7'Q+T%+_Q/I44
MEP+>:<M(F^)K2:#*A0`$E5V!R1)T``9Z'H_AKP[\%/\`@\>TC1_@;9Z?8:?K
M_AV=OB)9:0H2TM[B2QN+BYWJHV1EGCT^5@O!E?G#LU='_P`$H_\`E:W_`&QO
M^P->_P#I7IM?:G_!('_@AGX`_P""3MOK_B&+7=3^(_Q8\8(8]<\9:K`L4\D3
M2"1H+>/<[0QO(%DDW22/(ZJ68A45:O[(O_!'W5?V9?\`@KI\:_VFKCQS8:OI
M_P`6+.>T@T&/3'AFT[S);23<TQD*OC[.PP$'W@?:BX,^2?\`@DN2/^#H3]MC
M'4V,O?&?])L_\]Z_/?\`X)>>)_VP=7_X*-_M'>,?@G\./AKX\^,46M7*^)I/
M&,EO]MT)I;ZY\U;,3W-N5!DC,<A0-M6.)3L!`/[D?L>?\$D-6_9?_P""K7QT
M_:/NO&VGZO8?&"!X(-#BTYX9M-S+!("TQD*O_JF&`HZC\/+/^"FG_!N/H_[7
M/[0\_P`;?@U\3_$GP#^,>H$?VGJFCO,+75#L$9E(AEBE@F954,\;[7QED+$L
M2XC\]_VROV4OVW?VVOVN?@GJOQ_T;]G#X#^*=!UR*YTCQ;%XATO3=5F1)XI`
M!']NEFO#"Z;XHT3AV8;E#$U[-^TQX>\/?%[_`(/!/"6A_';^SKGPEI'AFS;P
M+8ZNR?8+V=;-I;=-K#:Y-\UVRJV-TJ*OS?*K?1O_``3[_P"#:?3O@-^U%IWQ
MP^/WQ:\1_M$?$S0&CFT236$E^Q:7<1N6BN#YTLLDTD1(,0+*D39<(6",GOO_
M``5Q_P""*/PW_P""M?A?1;C7M0U3P9\0?"*N-`\6:2JFZM5)+"&9#CSH!)AP
MH9&5LE'7<VX&8G_!Q3\-OACXJ_X)$?%^[^(=AH)_L'0Y+GPU<WC+!-9ZN,?8
MQ;R<,)'FV+L4_O%9E8%217P+^RSX>\5_#[_@U;^$L*6MW;VGB'Q3<W>I(8R"
M-/DU&_D@=O\`8>:.V8$]=Z>N:[WP1_P:B>-_B]XTT1?VE?VK_B%\7_`OAN83
MVGAX2W@,[!AP9KFYF\I60NC>6GF;6PLB8%?K;K'[.G@G6O@,/AB_AS38/`B:
M6FBPZ-;1_9[:UM(T"111!,>6$55VE<%2H(P17I9-CXX/'4<5./,H23:]'T\^
MWF<.9X66*PE3#Q=G)-7_`*Z=_(Y_]CGP'X(\-?LI^#M.\%VVF3^%KS1H65XD
M1TO]\8\UY>NYV8OO#9.XL#TQ7Q-_P3?\`>&M!_X+"?&UO`D=L/!VC:7<VL(M
M!_HUO++<VC/%'@;1&LL<ZJ!QA1MRHXV;G_@AUXR\&W%YH_@+]H+Q;X;\$WTK
M,VF.L^Y%9<-O$,\44S$C!.Q,CZ<_6'[%/[#G@W]AGX<SZ'X76XO+_4W6;5=6
MO`IN]1D4$*#M`"QIN8(@X7<QR69F;Z>OC<#@\/BI8?$NM*NK6Y9*UY)N4V]'
M)*Z5KZM]&>#3PV+Q-;#JM05*-%WO=.]E9*-M4GN[VV74^1?^"2&B6OBG_@H)
M^TOX@U"W@OM7T_6IHK:[E7S9+=9;^[WA&(X!$2#C'"@=,TMYHT'@'_@X7TU=
M*M_L47B/1WN+Y8(V$<SMITNYGY"C<\*$D`@OCC<Q8?1W[%_[!-S^R?\`&_XJ
M^,;CQ/#KO_"RM0^W);)8>0;#-Q<3;2Y=M_\`K@,@*/ESCD`+XB_8&EU[_@HO
MHGQY'B:W@ATC3S9-HW]F[Y+@_99H-_VCS/D(,JGA"2%*YP36]?/,)+,,5553
MW)T.2.CUER125K:>\GTM?6_4RIY5B%@\/!P]Z-7F>JVYY.][ZZ->?0^:OV1]
M,TGQ]_P6H^,TOQ"M[6Y\5:.)6\-07R^8L<4;Q)'+$&``D%L8V4`9`=V&<%J]
M$_X+U>$/!]_^QH=9UF#3U\5Z?J=M#X?N&PMTSO(//B4CED,(=F4_+F-3U5:[
MK]N;_@ESH7[7/C*Q\:Z)XAO_`(?_`!%TX1HFN6,;2>>L>=F]%=")%!PLJL&`
M`!W!5`\'\2_\$*/%?Q>\.7,_Q`^.FO\`B7Q-`D<6DS7$$MU:V"A@)=XEE+R;
MT5?N&/##<Q?I73A,RRRKC,+F57$NE[)0BX<LFURI+W6M.66[ZVOHVS#$8+'4
M\-B,#"@JGM')J=TK\VNJ>O,NG2]M3F_^"FG_``3+\<?\%AO^":G[/_B+P3XI
ML="^+G@"TL/$NE3:DSK::C)+:1>=&T@#&.3S(XI$D*N,QE6`#[T\Z_8__P""
MS_[4G[.7[=7PY_9W_;4^&&A:9J'Q)N_L?AWQ=I/EQB>=OW<1*PO)!,&F98B8
M_*9/-4E2#S]0?MN?\$H?B-^T)^R9\'/!7PU^/.O?"#QG\((XEAU_2(9XUU8+
M;I"T<@BGC=4)0-M)<'H0:\E_8K_X($?$/P_^V=X7^._[3_Q_U?X[^+OA\O\`
MQ2M@UO)%8Z9+A\3,9&.2I8.JHB?.H9B^`!^?XV<)8BI*E\+D[>E]/P/L<-&<
M:,%/=)7];:GS#\'O!7@?XY_\'?\`\8++XY0:7JE]HFFQ2^`=,UU_,M9;N"UL
M&MO(BD&QW6W\^=$`P'WR`%EW#]?OV[].M]._80^-:V\$,`_X0'6UQ&@08&G3
MX''85\Y_\%=?^""_P[_X*JZUH?C`Z_JOPV^*WAA$BT[Q5I$*O+)'&Y>..=,H
MTFQB61U=7C/0XRIYC_@G_P#\$:?B]^RE\%/CSX/^(?[27B+XR)\6?#+:!H\F
MLK>R1^'7:"\B>94GNIOO_:8RP3:3Y7)/&.:YN?GU_P`$S_$'B;PQ_P`&A/[2
M%WX39UU<:AK$,C+D,MG(MA'>D8(((M'G.>U<)_P1#UO]O_X9?L.:5/\`LQ?!
MGX':[X'UN^O)[C7KZ>R.KZI<"9D=;QFOXW!C`"(C1KB,*<')8_L;_P`$=O\`
M@E0?^"9G[#>K?!CQ1XATGXCVFM:Q?WUY)_99M[6YM[J*.)K>2&1Y`RE$(8$X
M(<C!'7XP^)__``:I>*_A?\4M<U+]F#]I_P`=_`WPCXGF,U]X<AFO3'`=I4!9
M;>YB,JJ&8()5+*#]\]:`//?^"-/[%_QTTS_@NCXF^+WQ3;X&?"OQ#+HEY;>)
M?!/@_P`16$UYJKO;VZG_`(EUM=3O;CS/LUS*[[5+A2$S)N%W_@@)I]G\4O\`
M@X"_;=\3^)-/@U/Q+HVJW\.G7US"IDL8_P"UI(6$6=V-T<42AU(RJ],-@?>W
M_!(__@B'\._^"4=GK^N6&K:KX]^*'C%=FN^+]7&+FX0OYC0Q)N;RXVE^=B69
MY&"EV;:H&#_P3/\`^"-.J_L!_MY_M`?&>^\?Z?XG@^-=_=7D.EV^CM9OI0FU
M"6["M(97$I`D"D[06(+'DT-B/BCXZ:#8_"O_`(/1/A/)X>L[;2&\6^&S<:N+
M9`BW\KZ/J4;.X'&XK!#DC&3&"<G.<_\`9:\'>"_CY_P=M?'VW^.,6EZKKWAF
MR)\!:3K;B>V+Q1V1MV@CE&UI5M&:=4'0R2R`,5WC[L^,/_!'+5/BA_P6[^'W
M[7$?CRPM--\$Z.NFOX:;2W>>[86M[;EA<"0*H_TI6^X?ND>AJO\`\%=/^"!'
MP_\`^"I/BC2/'=GXEUCX6?%[P_`+>T\5Z/")3=1IDQ)<Q!D9S&Q.R1)$=02"
M6`4*7T&=+_P<!:GXC\!_\$:OCS<^!K>2WU)O#ZV]RUE'MDBL))XHKQ@%'W1:
MM*&/\*;CVK\?_P#@B?XB_;^^'G[#NDS_`+,?P7^!6M^!-7NKIKC6KN2Q.K:I
M<"9T?[:S7\<FY,;%5T4+&$P,')_6/_@DW_P29^)/["VE_$_2/C#\>M=_:&T#
MQ_:6MC;:=KZ7<MMI\2"Y6X7R[FXG4B=9T5@NT$1@-NXQ\I^/_P#@U+\6?!_X
MF:Y??LO_`+4'COX)^$?$SEKS0!+>2_9P3PB3P7$32J@X0R@R`<&1CDDN!P7_
M``1@_8M^.7AW_@NAXI^+/Q1?X%_"3Q#=:!>Q^)O`O@W7M.FO-;:6.%2QTZWN
MIWME,ZPW4LIVAI8Q\N96(A\1_L)_MR?\$)OCA\7_`!Y^S38^%/B]\(/&NJ/X
MDU'3=2B6YU2.)#+(%FC+Q3M)&LT@WV\C>8%#%`3LK]"?^"1W_!$;X>?\$HK#
MQ!K5AJVJ>/?B?XR`&O>+]74"ZN$W>8T,*Y;RHVE)=_F9Y&"EV;8@7Y.^(O\`
MP;X_M8G7/%&@>"?VY_&FC?"[Q3?W<QTB]%_//I]K/O!MD/VD[E".5(5XU.`<
M9Y!<#[=_X(Z?\%*])_X*J_L8V'Q.L/#X\*:G'J-QI6M:0LXGCM;V/:[LC@*6
M1UD1P64'YB#G&3\7?\')7_!$?Q_^V+XW\*?M$_`:61_BW\/[6&WNM)BF$%QJ
M4%K+)<6US:,1C[7#*Y&QB-Z[<$-&%?\`0#_@FO\`\$^_"/\`P3(_9)\/?"?P
M?<76I6VE-)=ZAJ=TBI<:O>RD&:X=5X7)`"KD[45%RV,GWF@#^:_]B7_@X(UE
M-4U?PC^U5\7/CM\+/%FBR&/[;I>G">!BNT&&YM&3[1!.,D\*RGGB/`#?>G@'
M]L+P-\5M$_M/PO\`M4?M"^)=-WF/[7I6A+>0;@<%=\:,N0>V:^P_V^_^"07P
M!_X*4Z25^*'@6QN]>CC$=MXCTX_8=9M0`=H%P@RZ#)Q'*'3_`&:_)WXF?\&L
M'[27[#/BZY\6_L>_M"ZFI+^:=)O-0ET#49%505C:6$M:W>6SQ,D*`$`@\FOH
ML%Q#4IJU>/.NEE!/YMPE<\7%9-";O1EROK=R:^Y25CZVO?C/H>I6DMO<_M!?
MM.7$$RE)(Y/"+.CJ>H(,6"/8U\1_M)?\$8?V2?CDNK:II?C#XU>%O%E_YLR7
MMK\/V^Q/.V2&EM41%*[CDB,QDY^]7E_QE_X*Y_\`!3/_`()SZ['9_'F#Q?!H
MPQ&-3G\/V"6TGSLBF.^@@:V=B1]PDL0%/R[LGZ'^#O\`P<@?#OXA?#F^U?Q'
M^U/\7_`>M:=;&4Z'??#;3[Z:^D``\NVFM]T3%F/'FF+'\6`"U>U_:F78NARU
MVHWZ-ZJW6\<._P`'?<\OZAC</5YJ2<K=4M/2TJR_%'Q!\*O^"A/[3'_!)3XS
M^'/AKX\^)GQ0D^![:@T-G>0+,LCZ<K*CSZ>+H;D:-3&QM6.U=V`%\Q9#^OWA
M_P#:3\/>*M!L=4T[]I#]IV\T_4K>.ZM9X_"CE)HG4,C@^5T*D$?6OR@T;P[^
MTM_P=,_M=Z/H_P#:>O'X/?#Z_GAC\0ZMI]O'#X<M)V0R23>0J1SWTL<46($8
MXVJ,J@>4_OSX!_8$^+WPP\#:-X;T3]IKQ)9Z-X?L8--L+?\`X1+3W$%O#&L4
M:`L23A$49)R<9/-<>6YCAJ-6I2<XJDG[M]?6S]C*37DXQ^^YTX[!5ZE.%11;
MFU[UM/P]K%)^C?Y'E/[/_P"V=X4^#7CB75M9^*?[0/CRTDM'MAINL>$YC;JS
M,A$HVQ`[E"D#GHQK[)_9X_:1\._M.^#[G7/#,>MQV5I=-9R?VEIDUC)YB@$A
M1(HW`9QE<@'(Z@BO(_\`AC[XY?\`1T?B3_PC]-I&_8\^.+J5/[4?B7D8X\(:
M:#2S-9;BO?A6C&>FMYVMZ*A'[PP+QV']V5*3CV]V_P![JR/INBO(M$^`7Q!T
M[1K.WN?C9XJN[F"%(Y9_[%TM?.<*`7P8"1DY."3UZGK17S3P]-.WM8_=+_Y$
M]U5Y_P#/M_\`DO\`\D>NT445R'0?G-_P44_X)._$S]J__@L9^S9\>_#5_P"$
M+?P5\(_L9UN'4+V:+4)?)OI;AO(C2%D?*.`-SKSZ#FOT9HHIW`^;_P#@KI^R
M;XJ_;G_X)T?$_P"%'@J[T>S\3^,;&WMK&7597BLP4NX)F$C(KLH*1L`0I^;;
MP1FM7_@EW^S+XA_8T_X)^?"GX7>+)]+N?$?@K0TTZ_DTV9YK1Y0[L3&[HC,N
M&')4?2O>Z*+@%%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"OA3_@M!_P`%U_!O_!'/3_"EEJ_@
MWQ%XW\5>-H+FXTRRM)%L[*..!HU=YKEPV#F082-';CYM@*D_==?`G_!:[_DK
M?[+G_8_3?^FZYH!GYJ>(/^"AO_!3?_@M/;W6D?!_X:S_``K^'.KJ+>6\M;);
M"&2"2+YB^IW^&D&"6!M%1@"N`3@GV/\`X)Z?\&97@OX>26'B#]HSQ@WCK5(C
MYC^&?#DDMIHZG'W9;I@EQ,,\_((?3YAU_;;PU_R+FG_]>T?_`*`*NT[@<W\)
M/@]X5^`GP]TSPGX*\/:/X5\-:/$(;+3-+M4MK:W7_910!DGDGJ2222:Z2BBD
+`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
